

**Request under Freedom of Information Act 2000**

Thank you for your request for information which we received on 18 February 2022.

I am pleased to confirm the following.

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) as a single agent  
**We are unable to answer as this is prescribed by the GP.**
- Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) - **3**
- Abemaciclib + Fulvestrant - **7**
- Anthracycline (e.g. doxorubicin or epirubicin) as a single agent - **0**
- Atezolizumab + Nab-paclitaxel/Paclitaxel - **3**
- Capecitabine as a single agent - **7**
- Carboplatin or Cisplatin as a single agent - **0**
- Eribulin as a single agent or in combination - **1**
- Everolimus + Exemestane - **0**
- Fulvestrant as a single agent - **0**
- Lapatinib - **0**
- Neratinib - **2**
- Parp Inhibitors (Olaparib/Talazoparib) - **2**
- Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) - **17**
- Palbociclib + Fulvestrant - **1**
- Pembrolizumab - **0**
- Pertuzumab + Trastuzumab + Docetaxel - **1**
- Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) - **9**
- Ribociclib + Fulvestrant - **8**
- Sacituzumab Govitecan - **0**
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent - **13**
- Trastuzumab as a single agent or in combination - **17**
- Trastuzumab emtansine - **6**
- Transtuzumab deruxtecan - **3**
- Vinorelbine as a single agent - **0**
- Any other active systemic anti-cancer therapy – **0**

Q2. In the past 3 months, how many early/locally advanced (Stages I to IIIc) breast cancer patients were treated with an Aromatase Inhibitor (anastrozole, exemestane, letrozole) as a single agent?

**We are unable to answer as this is prescribed by the GP.**

You are advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely,

Freedom of Information Co-ordinator  
For and on behalf of Milton Keynes Hospital NHS Foundation Trust

|   |
|---|
| <p>Any re-use of this information will be subject to the<br/>'Re-use of Public Sector Information Regulations' and best practice.</p> |
|---|